Viridian Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
I'm PortAI, I can summarize articles.
Rami Katkhuda has rated Viridian Therapeutics as a Buy due to promising developments in its pipeline, particularly VRDN-003, which has completed enrollment in the pivotal REVEAL program for Thyroid Eye Disease. The potential for a Biologics License Application submission by next year, along with a new patent for VRDN-003 and the anticipated launch of veligrotug in 2026, supports this rating. Katkhuda, a 5-star analyst, has a 30.7% average return and a 53.33% success rate. Wedbush also maintains a Buy rating with a $40 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments